000			01857 a2200553 4500
005			20250516174626.0
264		0	_c20140831
008			201408s 0 0 eng d
022			_a1873-2763
024	7		_a10.1016/j.bone.2013.10.006 _2doi
040			_aNLM _beng _cNLM
100	1		_aRoux, C
245	0	0	_aDenosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. _h[electronic resource]
260			_bBone _cJan 2014
300			_a48-54 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAlendronate _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone Density Conservation Agents _xadverse effects
650	0	4	_aCollagen Type I _xblood
650	0	4	_aDemography
650	0	4	_aDenosumab
650	0	4	_aEtidronic Acid _xanalogs & derivatives
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMedication Adherence
650	0	4	_aOsteoporosis, Postmenopausal _xblood
650	0	4	_aPeptides _xblood
650	0	4	_aRisedronic Acid
650	0	4	_aTreatment Outcome
700	1		_aHofbauer, L C
700	1		_aHo, P R
700	1		_aWark, J D
700	1		_aZillikens, M C
700	1		_aFahrleitner-Pammer, A
700	1		_aHawkins, F
700	1		_aMicaelo, M
700	1		_aMinisola, S
700	1		_aPapaioannou, N
700	1		_aStone, M
700	1		_aFerreira, I
700	1		_aSiddhanti, S
700	1		_aWagman, R B
700	1		_aBrown, J P
773	0		_tBone _gvol. 58 _gp. 48-54
856	4	0	_uhttps://doi.org/10.1016/j.bone.2013.10.006 _zAvailable from publisher's website
999			_c23185670 _d23185670